
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...
By Andrew Storaska and Jennifer P. Nock Comments are off
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...
Tagged with: District Court, Dupixent®, Follow-on petitions, Genzyme, Immunex, IPR, PTAB, Regeneron, Sanofi
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Aydin Harston Comments are off
Biologic drugs are large molecules, such as therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins, that are...
Tagged with: Amgen, Apotex, BLA, FDA, Federal Circuit, filgrastim, IPR, Neulasta®, Neupogen®, pegfilgrastim, PTAB
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Spencer Johnson Comments are off
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
Tagged with: BLA, Boehringer Ingelheim, BPCIA, Celltrion, District Court, Genentech, Herceptin®, IPR, Litigation, Mylan, Pfizer, Samsung Bioepsis, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Monica Chin Kitts Comments are off
Sandoz’s request for inter partes review (“IPR”) of U.S. Patent Numbers 9,512,216 (“the ’216 patent”) and 8,802,100 (“the...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...
Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Nicole DeAbrantes Comments are off
On December 5, 2017, the Federal Circuit held oral argument in Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, 17-1694. The...
Tagged with: abatacept, Bristol-Myers Squibb, Federal Circuit, IPR, Momenta Pharmaceuticals, Orencia®, PTAB
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Spencer Johnson Comments are off
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By Caitlin M. Wilmot Comments are off
On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...
Tagged with: AbbVie, Amgen, Boehringer Ingelheim, Coherus, Humira®, IPR, Legal, PTAB, Samsung Bioepsis, Sandoz
ShareEmail, Linked In, Twitter, Facebook, Google Plus